Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volasertib and Liposomal Vincristine in Relapsed/Refractory ALL
NCT02861040Phase 1Withdrawn
- Sponsor
- Northwestern University
- Start
- Aug 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of volasertib in acute lymphoblastic leukemia (ALL), sponsored by Northwestern University. Primary endpoint: Maximum Tolerated Dose. Planned start Aug 2016; status: withdrawn.
02
Drugs
volasertib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02861040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02861040.